Christopher Bunick
Dermatology · New Haven, CTNPI 1457527442
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $494,198 of the $661,460 with a category attached, or 74.7%. It is spread thinly across 28 manufacturers, the largest accounting for just 22.1%. 2025 is the largest year on record at $238,787, 6.1 times the $39,005 reported in 2019. Among dermatology clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 693 payments — averaging $954.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- LEO Pharma Inc.$146K
- AbbVie$92K
- UCB, Inc.$90K
- Almirall LLC$77K
- Arcutis Biotherapeutics, Inc.$46K
- Pfizer$43K
- plus $167K from 22 others
Across 83 payments — averaging $12,293 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Almirall LLC$568K
- AbbVie$154K
- Bausch Health US, LLC$125K
- Daiichi Sankyo Inc.$56K
- Daiichi Sankyo Company LTD$55K
- Takeda Pharmaceuticals U.S.A., Inc.$45K
- plus $18K from 2 others
What the payments were for
- Consulting fees$494,19875%
- Speaking & faculty fees$110,83117%
- Travel & lodging$33,0105%
- Food & beverage$22,8083%
- Education$6130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| LEO Pharma Inc. | 141 | $145,925 |
| AbbVie | 92 | $92,047 |
| UCB, Inc. | 136 | $90,251 |
| Almirall LLC | 65 | $77,334 |
| Arcutis Biotherapeutics, Inc. | 39 | $46,244 |
| Pfizer | 61 | $43,006 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $42,990 |
| Novartis | 19 | $26,034 |
| Sanofi | 29 | $15,357 |
| Sun Pharmaceutical Industries Inc. | 12 | $15,117 |
| Sanofi US Services Inc. | 3 | $14,936 |
| Incyte Corporation | 16 | $13,522 |
| Eli Lilly | 10 | $12,617 |
| LEO Pharma AS | 2 | $6,675 |
| Galderma Laboratories, L.p. | 8 | $5,790 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 6 | $4,207 |
| Regeneron | 4 | $3,313 |
| Regeneron Healthcare Solutions, Inc. | 5 | $1,990 |
| EPI Health, LLC | 4 | $1,649 |
| Biofrontera Inc. | 1 | $1,500 |
| Boehringer Ingelheim | 1 | $228 |
| Sanofi-aventis U.S. LLC | 3 | $182 |
| E.r. Squibb & Sons, L.L.C. | 5 | $162 |
| Lilly USA, LLC | 4 | $148 |
| Janssen Research & Development, LLC | 2 | $87 |
| Amgen | 3 | $82 |
| Verrica Pharmaceuticals Inc. | 1 | $54 |
| Janssen Global Services, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$661,460 in reported general payments places this provider in the 95th percentile of 222 dermatology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 41 | $805,619 |
| SkyriziRisankizumab-Rzaa | 23 | $486,969 |
| Dupixent PenDupilumab | 105 | $356,245 |
| Dupixent SyringeDupilumab | 68 | $288,906 |
| AdbryTralokinumab-Ldrm | 23 | $87,562 |
| OtezlaApremilast | 12 | $59,494 |
| ZoryveRoflumilast | 18 | $18,058 |
| Clobetasol Propionate | 212 | $8,275 |
| Doxycycline Hyclate | 60 | $3,553 |
| Ivermectin | 14 | $2,647 |
| Tacrolimus | 24 | $2,348 |
| Tretinoin | 35 | $2,347 |
| Adapalene | 19 | $2,322 |
| Triamcinolone Acetonide | 193 | $2,297 |
| ErtapenemErtapenem Sodium | 22 | $2,289 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieSkyrizi | $92,047 | $486,96923 claims |
| LEO Pharma Inc.Adbry | $145,925 | $87,56223 claims |
| AmgenOtezla | $82 | $59,49412 claims |
| Arcutis Biotherapeutics, Inc.Zoryve | $46,244 | $18,05818 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 222 dermatology providers in Connecticut.
Other dermatology in New Haven
- Keith ChoateNew Haven$362K
- David LeffellNew Haven$94K
- Mariam TotonchyNew Haven$52K
- Lisa DonofrioNew Haven$38K
- Richard AntayaNew Haven$37K
- Leonard MilstoneNew Haven$31K
- William DamskyNew Haven$23K
- Michael GirardiNew Haven$20K
- Jeffrey CohenNew Haven$18K
- Mary TomaykoNew Haven$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.